Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss

This article was originally published on Nasdaq

Allogene Therapeutics, Inc. ALLO incurred a loss of 53 cents per share in second-quarter 2023, narrower than the Zacks Consensus Estimate of a loss of 59 cents. In the year-ago quarter, the company reported a loss of 52 cents.